Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Amicus Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, CRISPR Therapeutics AG and Amicus Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Amicus Therapeutics saw a staggering 1,230% increase in SG&A expenses, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, CRISPR Therapeutics managed a more modest 1,390% rise, indicating a more controlled approach to cost management.

While Amicus's expenses peaked at nearly 275 million in 2023, CRISPR's expenses remained below 103 million, showcasing a strategic focus on cost efficiency. This comparison highlights the diverse strategies employed by biotech firms in balancing growth with financial prudence. As the industry evolves, these insights offer valuable lessons for emerging companies aiming to optimize their operational costs.